Clinical Trial

Recent News

07/30/2015
GI Dynamics Concludes ENDO Trial
Read More

07/30/2015
Appendix 4C Quarterly Report Quarter Ended 30 June 2015
Read More

06/08/2015
New Data Presented at ADA Demonstrate Early Effect of EndoBarrier Therapy on Glucose Control and Bil...
Read More


The GI Dynamics’ EndoBarrier® Gastrointestinal Liner System is used for the treatment of obese type 2 diabetes with BMI ≥ 30 kg/m2, or obese patients with BMI ≥ 30 kg/m2 with ≥ 1 comorbidities, or obese patients with BMI >35 kg/m2.
The liner is indicated for maximum implant duration of 12 months.
EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE